Pricing
  1. US-listed companies
  2. Ascendis Pharma A
  3. Financials
  4. Research & development

Ascendis Pharma A (ASND)

Market cap
P/E ratio
SummaryFinancials
Period EndResearch & development (Million EUR)YoY (%)
Dec 31, 2024307-25.75%
Dec 31, 2023413+8.91%
Dec 31, 2022380+28.31%
Dec 31, 2021296+13.40%
Dec 31, 2020261+36.16%
Dec 31, 2019192+36.60%
Dec 31, 2018140+40.86%
Dec 31, 2017100

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat